According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...
Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...
WASHINGTON -- Extended pelvic lymph node dissection (ePLND) after radical prostatectomy failed to improve survival in intermediate- and high-risk prostate cancer over standard lymphadenectomy, ...
Removing lymph nodes during cancer surgery has saved countless lives in many tumour types. Yet recent research is challenging parts of this long-standing practice. Imagine your body’s immune defences ...
Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does ...